Recro Pharma, Inc. (NASDAQ:REPH) was founded in 2007, formerly known as Recro Pharma I, Inc., changed to its current name in August 2008, headquartered in Malvern, Pennsylvania, USA, with 255 full-time employees, is a specialist A pharmaceutical company engaged in the development of non-opioid drug products in the United States, mainly for the treatment of acute pain.
Recro Pharma, Inc. (REPH):
Recro Pharma’s main drug candidates include: injectable meloxicam (meloxicam), which has completed a pivotal phase III clinical trial for the treatment of postoperative pain.
In addition, Recro Pharma has also developed Dex-IN, an intranasal dexmedetomidine for the treatment of postoperative pain and perioperative pain; two new neuromuscular blockers and related patented chemical reversal agents ; And Fadolmidine are used as human therapeutics.
In addition, the company also provides contract development and manufacturing services.
Recro Pharma, Inc. has signed a license agreement with Orion Corporation for the development and commercialization of Dexmedetomidine.
Recro Pharma focuses on providing products for hospitals and related markets.
On September 4, 2018, Recro Pharma, Inc. received the official meeting minutes of the Type A meeting held with the U.S. Food and Drug Administration (FDA) in July 2018, and provided regulatory updates. The meeting involved the company’s main The development process of the product intravenous (IV) meloxicam (a candidate product for the treatment of moderate to severe pain). The company’s share price soared +26.49%.